Evidence map›Paper›PMID 28806394›Full record

ArticleOncogene2017

SmgGDS is a transient nucleolar protein that protects cells from nucleolar stress and promotes the cell cycle by regulating DREAM complex gene expression.

P Gonyo, C Bergom, A C Brandt, S-W Tsaih, Y Sun, T M Bigley, E L Lorimer, S S Terhune, H Rui, M J Flister and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

P GonyoDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
C BergomCancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
A C BrandtDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
S-W TsaihDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Y SunDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
T M BigleyDepartment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.
E L LorimerDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
S S TerhuneDepartment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.
H RuiCancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
M J FlisterCancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
R M LongDepartment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.
C L WilliamsDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin · US

Funding

Leveraging genetic mapping for personalized targeting of breast cancer microenvironmentR01CA193343 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amit Joshi · 2015 to 2026
$3.5M
Impact of HCMV proteins on viral replication and cellular signaling pathwaysR01AI083281 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI TERHUNE, SCOTT SLETTEN · 2011 to 2020
$3.2M
Prolactin pathways and metastatic progression of ER-positive breast cancerR01CA188575 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RUI, HALLGEIR · 2015 to 2019
$1.8M
Regulation of Rap1 Prenylation and Trafficking in Breast CancerR01CA188871 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI WILLIAMS, CAROL LUCILLE · 2015 to 2019
$1.7M
Clinical and Translational Science AwardKL2TR000056 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI SHAKER, REZA NONE · 2012 to 2015
$609k
NCATS NIH HHS KL2 TR000056NCI NIH HHS R01 CA188575NCI NIH HHS R01 CA188871NCI NIH HHS R01 CA193343NIAID NIH HHS R01 AI083281
6 · The paper itself

Abstract

The chaperone protein and guanine nucleotide exchange factor SmgGDS (RAP1GDS1) is a key promoter of cancer cell proliferation and tumorigenesis. SmgGDS undergoes nucleocytoplasmic shuttling, suggesting that it has both cytoplasmic and nuclear functions that promote cancer. Previous studies indicate that SmgGDS binds cytoplasmic small GTPases and promotes their trafficking to the plasma membrane. In contrast, little is known about the functions of SmgGDS in the nucleus, or how these nuclear functions might benefit cancer cells. Here we show unique nuclear localization and regulation of gene transcription pathways by SmgGDS. Strikingly, SmgGDS depletion significantly reduces expression of over 600 gene products that are targets of the DREAM complex, which is a transcription factor complex that regulates expression of proteins controlling the cell cycle. The cell cycle regulators E2F1, MYC, MYBL2 (B-Myb) and FOXM1 are among the DREAM targets that are diminished by SmgGDS depletion. E2F1 is well known to promote G1 cell cycle progression, and the loss of E2F1 in SmgGDS-depleted cells provides an explanation for previous reports that SmgGDS depletion characteristically causes a G1 cell cycle arrest. We show that SmgGDS localizes in nucleoli, and that RNAi-mediated depletion of SmgGDS in cancer cells disrupts nucleolar morphology, signifying nucleolar stress. We show that nucleolar SmgGDS interacts with the RNA polymerase I transcription factor upstream binding factor (UBF). The RNAi-mediated depletion of UBF diminishes nucleolar localization of SmgGDS and promotes proteasome-mediated degradation of SmgGDS, indicating that nucleolar sequestration of SmgGDS by UBF stabilizes SmgGDS protein. The ability of SmgGDS to interact with UBF and localize in the nucleolus is diminished by expressing DiRas1 or DiRas2, which are small GTPases that bind SmgGDS and act as tumor suppressors. Taken together, our results support a novel nuclear role for SmgGDS in protecting malignant cells from nucleolar stress, thus promoting cell cycle progression and tumorigenesis.

Indexed as

CytoprotectionGene Expression RegulationCarcinogenesisCell CycleCell Line, TumorCell NucleolusGuanine Nucleotide Exchange FactorsHumansKv Channel-Interacting ProteinsRepressor ProteinsGuanine Nucleotide Exchange FactorsKCNIP3 protein, humanKv Channel-Interacting ProteinsRAP1GDS1 protein, humanRepressor Proteins

Identifiers

PMID28806394
PMCPMC5730474
OpenAlexW2745520713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.